Effects of proton pump inhibitors on the gastric mucosa-associated microbiota in dyspeptic patients

Applied and Environmental Microbiology

Volumn 82, Issue 22, 2016, Pages 6633-6644

  Sterbini, Francesco Paroni ^a   Palladini, Alessandra ^a,b,c,d   Masucci, Luca ^a   Cannistraci, Carlo Vittorio ^b   Pastorino, Roberta ^a   Ianiro, Gianluca ^a   Bugli, Francesca ^a   Martini, Cecilia ^a   Ricciardi, Walter ^a   Gasbarrini, Antonio ^a   Sanguinetti, Maurizio ^a   Cammarota, Giovanni ^a   Posteraro, Brunella ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

HELICOBACTER PYLORI; MICROBIAL COMMUNITIES; MICROBIAL COMPOSITION; MICROBIAL POPULATIONS; MICROBIAL SPECIES; PRINCIPAL COORDINATE ANALYSIS; PROTON PUMP INHIBITORS; RELATIVE ABUNDANCE;

PATIENT TREATMENT;

ABUNDANCE; BACTERIUM; DIGESTIVE SYSTEM; DIGESTIVE SYSTEM DISORDER; GENETIC ANALYSIS; INFECTIOUS DISEASE; INHIBITOR; MICROBIAL COMMUNITY; PRINCIPAL COMPONENT ANALYSIS; RELATIVE ABUNDANCE;

ACTINOBACTERIA; BACTEROIDETES; FIRMICUTES; FUSOBACTERIA; HELICOBACTER; HELICOBACTER PYLORI; PREVOTELLA; PROTEOBACTERIA; STREPTOCOCCACEAE; STREPTOCOCCUS;

ANTIINFECTIVE AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RNA 16S;

ADULT; AGED; BACTERIUM; BACTEROIDETES; CLASSIFICATION; DRUG EFFECTS; DYSPEPSIA; FEMALE; FIRMICUTES; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HIGH THROUGHPUT SEQUENCING; HUMAN; INTESTINE FLORA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PROTEOBACTERIA; RNA GENE; STOMACH MUCOSA; STREPTOCOCCUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; BACTEROIDETES; DYSPEPSIA; FEMALE; FIRMICUTES; GASTRIC MUCOSA; GASTROINTESTINAL MICROBIOME; GENES, RRNA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; OMEPRAZOLE; PROTEOBACTERIA; PROTON PUMP INHIBITORS; RNA, RIBOSOMAL, 16S; STREPTOCOCCUS;

EID: 84995474861     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01437-16     Document Type: Article

References (57)

1. +-ATPase. Compr Physiol 1:2141-2153. http://dx.doi.org/10.1002/cphy.c110010.
2. Yang YX, Metz DC. 2010. Safety of proton pump inhibitor exposure. Gastroenterology 139:1115-1127. http://dx.doi.org/10.1053/j.gastro.2010.08.023.
3. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. 2012. Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report. Gut 61:646-664. http://dx.doi.org/10.1136/gutjnl-2012-302084.
4. Williams C, McColl KE. 2006. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 23:3-10. http://dx.doi.org/10.1111/j.1365-2036.2006.02707.x.
5. Wang LL, Yu XJ, Zhan SH, Jia SJ, Tian ZB, Dong QJ. 2014. Participation of microbiota in the development of gastric cancer. World J Gastroenterol 20:4948-4952. http://dx.doi.org/10.3748/wjg.v20.i17.4948.
6. Walker MM, Talley NJ. 2014. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract-beyond the era of Helicobacter pylori. Aliment Pharmacol Ther 39:767-779. http://dx.doi.org/10.1111/apt.12666.
7. Vesper BJ, Jawdi A, Altman KW, Haines GK, III, Tao L, Radosevich JA. 2009. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab 10:84-89. http://dx.doi.org/10.2174/138920009787048392.
8. Del Piano M, Pagliarulo M, Tari R, Carmagnola S, Balzarini M, Lorenzini P, Pane M. 2014. Correlation between chronic treatment with proton pump inhibitors and bacterial overgrowth in the stomach: any possible beneficial role for selected lactobacilli? J Clin Gastroenterol 48(Suppl 1): S40-S46. http://dx.doi.org/10.1097/MCG.0000000000000256.
9. Bengmark S. 2013. Gut microbiota, immune development and function. Pharmacol Res 69:87-113. http://dx.doi.org/10.1016/j.phrs.2012.09.002.
10. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrügger RW. 2001. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 15:379-388. http://dx.doi.org/10.1046/j.1365-2036.2001.00888.x.
11. Tsuda A, Suda W, Morita H, Takanashi K, Takagi A, Koga Y, Hattori M. 2015. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol 6:e89. http://dx.doi.org/10.1038/ctg.2015.20.
12. Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. 2014. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol 16:2905-2914. http://dx.doi.org/10.1111/1462-2920.12285.
13. Eun CS, Kim BK, Han DS, Kim SY, Kim KM, Choi BY, Song KS, Kim YS, Kim JF. 2014. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 19:407-416. http://dx.doi.org/10.1111/hel.12145.
14. Talley NJ, Holtmann G, Walker MM. 2015. Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. J Gastroenterol 50:601-613. http://dx.doi.org/10.1007/s00535-015-1076-x.
15. Ford AC, Moayyedi P. 2013. Dyspepsia. Curr Opin Gastroenterol 29: 662-668. http://dx.doi.org/10.1097/MOG.0b013e328365d45d.
16. Moayyedi P, Talley NJ. 2006. Gastro-oesophageal reflux disease. Lancet 367:2086-2100. http://dx.doi.org/10.1016/S0140-6736(06)68932-0.
17. Karamanolis GP, Tack J. 2012. Current management of functional dyspepsia: impact of Rome III subdivision. Ann Gastroenterol 25:96-99.
18. Zullo A, Hassan C, De Francesco V, Repici A, Manta R, Tomao S, Annibale B, Vaira D. 2014. Helicobacter pylori and functional dyspepsia: an unsolved issue? World J Gastroenterol 20:8957-8963.
19. Lacy BE, Talley NJ, Locke GR, III, Bouras EP, DiBaise JK, El-Serag HB, Abraham BP, Howden CW, Moayyedi P, Prather C. 2012. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 36:3-15. http://dx.doi.org/10.1111/j.1365-2036.2012.05128.x.
20. Freedberg DE, Lebwohl B, Abrams JA. 2014. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med 34: 771-785. http://dx.doi.org/10.1016/j.cll.2014.08.008.
21. McDonald EG, Milligan J, Frenette C, Lee TC. 2015. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 175:784-791. http://dx.doi.org/10.1001/jamainternmed.2015.42.
22. Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE. 2015. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci 60:2280-2286. http://dx.doi.org/10.1007/s10620-015-3642-8.
23. Boardman HF, Delaney BC, Haag S. 2015. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-thecounter proton-pump inhibitors. Curr Med Res Opin 31:1309-1318. http://dx.doi.org/10.1185/03007995.2015.1047745.
24. Mégraud F, Bessède E, Lehours P. 2014. Diagnosis of Helicobacter pylori infection. Helicobacter 19(Suppl 1):S6-S10. http://dx.doi.org/10.1111/hel.12161.
25. Yang I, Nell S, Suerbaum S. 2013. Survival in hostile territory: the microbiota of the stomach. FEMS Microbiol Rev 37:736-761. http://dx.doi.org/10.1111/1574-6976.12027.
26. Hamady M, Walker JJ, Harris JK, Gold NJ, Knight R. 2008. Errorcorrecting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods 5:235-237. http://dx.doi.org/10.1038/nmeth.1184.
27. Soergel DA, Dey N, Knight R, Brenner SE. 2012. Selection of primers for optimal taxonomic classification of environmental 16S rRNA gene sequences. ISME J 6:1440-1444. http://dx.doi.org/10.1038/ismej.2011.208.
28. Binladen J, Gilbert MT, Bollback JP, Panitz F, Bendixen C, Nielsen R, Willerslev E. 2007. The use of coded PCR primers enables highthroughput sequencing of multiple homolog amplification products by 454 parallel sequencing. PLoS One 2:e197. http://dx.doi.org/10.1371/journal.pone.0000197.
29. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335-336. http://dx.doi.org/10.1038/nmeth.f.303.
30. Reeder J, Knight R. 2010. Rapidly denoising pyrosequencing amplicon reads by exploiting rank-abundance distributions. Nat Methods 7:668-669. http://dx.doi.org/10.1038/nmeth0910-668b.
31. Gevers D, Cohan FM, Lawrence JG, Spratt BG, Coenye T, Feil EJ, Stackebrandt E, Van de Peer Y, Vandamme P, Thompson FL, Swings J. 2005. Opinion: Re-evaluating prokaryotic species. Nat Rev Microbiol 3:733-739. http://dx.doi.org/10.1038/nrmicro1236.
32. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. 2011. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27: 2194-2200. http://dx.doi.org/10.1093/bioinformatics/btr381.
33. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. 2010. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics 26:266-267. http://dx.doi.org/10.1093/bioinformatics/btp636.
34. Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26:2460-2461. http://dx.doi.org/10.1093/bioinformatics/btq461.
35. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS One 5:e9490. http://dx.doi.org/10.1371/journal.pone.0009490.
36. Good IJ. 1953. The population frequencies of species and the estimation of population parameters. Biometrika 40:237-264. http://dx.doi.org/10.1093/biomet/40.3-4.237.
37. Lozupone C, Hamady M, Knight R. 2006. UniFrac-an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinformatics 7:371. http://dx.doi.org/10.1186/1471-2105-7-371.
38. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. 2011. Metagenomic biomarker discovery and explanation. Genome Biol 12:R60. http://dx.doi.org/10.1186/gb-2011-12-6-r60.
39. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, Perez-Perez G, Blaser MJ, Relman DA. 2006. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A 103:732-737. http://dx.doi.org/10.1073/pnas.0506655103.
40. Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. 2008. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One 3:e2836. http://dx.doi.org/10.1371/journal.pone.0002836.
41. Li XX, Wong GL, To KF, Wong VW, Lai LH, Chow DK, Lau JY, Sung JJ, Ding C. 2009. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One 4:e7985. http://dx.doi.org/10.1371/journal.pone.0007985.
42. Engstrand L, Lindberg M. 2013. Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol 27:39-45. http://dx.doi.org/10.1016/j.bpg.2013.03.016.
43. Delgado S, Cabrera-Rubio R, Mira A, Suárez A, Mayo B. 2013. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol 65:763-772. http://dx.doi.org/10.1007/s00248-013-0192-5.
44. Rosen R, Hu L, Amirault J, Khatwa U, Ward DV, Onderdonk A. 2015. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr 166:917-923. http://dx.doi.org/10.1016/j.jpeds.2014.12.067.
45. Stearns JC, Lynch MD, Senadheera DB, Tenenbaum HC, Goldberg MB, Cvitkovitch DG, Croitoru K, Moreno-Hagelsieb G, Neufeld JD. 2011. Bacterial biogeography of the human digestive tract. Sci Rep 1:170. http://dx.doi.org/10.1038/srep00170.
46. Dicksved J, Lindberg M, Rosenquist M, Enroth H, Jansson JK, Engstrand L. 2009. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol 58:509-516. http://dx.doi.org/10.1099/jmm.0.007302-0.
47. Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, Karaoz U, Contreras M, Blaser MJ, Brodie EL, Dominguez-Bello MG. 2011. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J 5:574-579. http://dx.doi.org/10.1038/ismej.2010.149.
48. Salama NR, Hartung ML, Müller A. 2013. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol 11:385-399. http://dx.doi.org/10.1038/nrmicro3016.
49. Atherton JC, Blaser MJ. 2009. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 119:2475-2487. http://dx.doi.org/10.1172/JCI38605.
50. Rolig AS, Cech C, Ahler E, Carter JE, Ottemann KM. 2013. The degree of Helicobacter pylori-triggered inflammation is manipulated by preinfection host microbiota. Infect Immun 81:1382-1389. http://dx.doi.org/10.1128/IAI.00044-13.
51. White JR, Nagarajan N, Pop M. 2009. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoSComput Biol 5:e1000352. http://dx.doi.org/10.1371/journal.pcbi.1000352.
52. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A. 2016. Proton pump inhibitors affect the gut microbiome. Gut 65:740-748. http://dx.doi.org/10.1136/gutjnl-2015-310376.
53. Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, Claesson MJ, Targownik LE. 2016. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther 43:974-984. http://dx.doi.org/10.1111/apt.13568.
54. Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ. 2016. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65:749-756. http://dx.doi.org/10.1136/gutjnl-2015-310861.
55. Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A, Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition (SIGENP). 2006. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and communityacquired pneumonia in children. Pediatrics 117:e817-e820. http://dx.doi.org/10.1542/peds.2005-1655.
56. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. 2007. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 167: 950-955. http://dx.doi.org/10.1001/archinte.167.9.950.
57. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS, China Gastric Cancer Study Group. 2004. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291:187-194. http://dx.doi.org/10.1001/jama.291.2.187.